Personalis Stock Price, News & Analysis

Personalis (Nasdaq: PSNL) announced Medicare coverage of its ultrasensitive NeXT Personal test for surveillance of breast cancer recurrence. Coverage applies to Medicare beneficiaries with stage II and III breast cancer (HR+/HER2-, HER2+, TNBC) for up to six years in the surveillance setting.

A published study reported NeXT Personal detected 100% of recurrent cases a median of ~15 months (and up to ~5 years) before radiographic imaging, and 100% of patients with consistently negative tests remained disease-free.

Personalis (Nasdaq: PSNL) reported Q3 2025 results on November 4, 2025, highlighting operational progress in its "Win‑in‑MRD" strategy and accelerating clinical adoption.

Key metrics: delivered 4,388 clinical tests (+26% sequential, +364% YoY); revenue $14.5M (down 44% vs $25.7M); gross margin 13.2% (vs 34.0%); net loss $21.7M or $0.24 per share; cash and short‑term investments $150.5M.

Commercial and clinical updates: submitted a third Medicare lung cancer dossier, presented NeoADAURA and LAURA trial data showing earlier MRD detection, and launched the CATE breast cancer utility study with Yale. Guidance: Q4 revenue $15.7–$20.7M; full‑year 2025 revenue $68.0–$73.0M (reduced); population sequencing guidance raised to $16.5–$17.0M; clinical test reimbursement now $1.5–$2.0M (reduced); gross margin guide 22–24%; expected full‑year net loss ≈$85M and cash usage ≈$75M.

Personalis (NASDAQ: PSNL) will release its third quarter 2025 financial results on Tuesday, November 4, 2025. A conference call and webcast to discuss results and recent highlights will be held the same day at 2:00 p.m. PT / 5:00 p.m. ET.

Domestic callers may dial 877-451-6152; international callers may dial 201-389-0879. The live webinar is available via the Events section at investors.personalis.com, and a replay will be archived on the company's website shortly after the call.

Personalis (Nasdaq: PSNL) reported new analysis from the AstraZeneca phase 3 LAURA trial showing that the NeXT Personal® ultrasensitive MRD test can monitor maintenance treatment response after chemoradiotherapy in unresectable stage III, EGFR-mutated NSCLC.

Key findings: Osimertinib treatment led to MRD clearance in most patients with post-CRT MRD, and NeXT Personal detected MRD progression with a median 5-month lead time ahead of Blinded Independent Central Review (BICR) assessed progression. The LAURA results will be presented at ESMO 2025. Prior studies cited include CALLA (detection up to ~16 months before imaging) and NeoADAURA.

Personalis (Nasdaq: PSNL), a precision oncology genomics company, has granted inducement stock options to its newly appointed Senior Vice President and Chief Information Officer. The award includes options to purchase 440,000 shares of common stock at $5.93 per share under the company's 2020 Inducement Plan.

The stock options have a four-year vesting schedule, with 25% vesting after one year and the remaining vesting monthly over the following three years. This grant complies with Nasdaq Rule 5635(c)(4) for new employee equity incentives.

Personalis (Nasdaq: PSNL) has announced a collaboration with Yale Cancer Center for the CATE clinical trial, focusing on ctDNA-guided treatment in breast cancer. The trial will utilize Personalis's NeXT Personal® test to detect early molecular signs of recurrence in HR+/HER2- breast cancer patients.

The prospective, multi-center trial aims to prevent metastatic relapse by using ultrasensitive ctDNA detection to guide early intervention with elacestrant therapy. The study specifically targets HR+/HER2- breast cancer, which represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.

Personalis (Nasdaq: PSNL) has announced significant new data from AstraZeneca's phase 3 NeoADAURA trial, demonstrating the superior performance of its NeXT Personal® MRD test in lung cancer patients. The study focused on patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer receiving neoadjuvant therapy.

The test showed higher baseline sensitivity for ctDNA detection compared to other gene-mutation based tests, proved to be strongly prognostic of clinical outcomes, and demonstrated association with major pathological response. Notably, the test detected cancer DNA up to 16 months ahead of standard imaging in cervical cancer patients. The company has recently submitted for Medicare coverage for NeXT Personal in lung cancer patients.

Personalis (Nasdaq: PSNL), a precision oncology genomics company, has announced its management team's participation in two upcoming investor conferences in New York. The company will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, at the Sheraton New York Times Square Hotel, and the Lake Street 9th Annual Best Ideas Growth Conference on September 11, 2025, at the Yale Club.

Personalis (Nasdaq: PSNL) reported Q2 2025 financial results, highlighting a 59% sequential growth in clinical test volume to 3,478 tests. However, revenue declined 24% year-over-year to $17.2 million. The company expanded its partnership with Tempus AI to include colorectal cancer and presented significant clinical data at ASCO 2025.

Q2 financial metrics showed a gross margin of 27.6% and a net loss of $20.1 million. The company ended the quarter with $173.2 million in cash. Personalis revised its full-year 2025 guidance downward, now expecting revenue between $70-80 million, with increased projected net loss of approximately $85 million.